Skip to content

Trial Summary

This study aims to find out whether treatment with alpelisib plus fulvestrant increases progression-free survival compared to capecitabine in women and men with eostrogen receptor positive (ER+), HER2-negative advanced breast cancer who have a PIKC3A mutation identified in circulating tumour DNA (ctDNA).



ACTRN/NCT /ethics:


Scientific title:

BCT 1901 (CAPTURE): Women or men with oestrogen receptor positive, HER2 negative advanced breast cancer and PIK3CA mutant circulating DNA will be randomised to evaluate treatment with alpelisib plus fulvestrant compared with capecitabine on progression free survival.

Sponsor / Cooperative group:

Breast Cancer Trials

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase II
Age Range18+ years
Tumour StreamBreast
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2020-03-01
Anticipated End Date2022-08-31

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorDr Amanda Townsend
Recruitment StatusRecruiting
HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Phone08 8282 0833
Principal InvestigatorDr Hooi Hong
Recruitment StatusRecruiting